Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHG Bright Health Group	$6.75 +1.0%	$6.82	$4.94 ▼ $82.40	$53.88M	0.93	72,717 shs	17,232 shs
CRGX CARGO Therapeutics	$4.46 -0.1%	$4.45	$3.00 ▼ $25.45	$215.44M	0.3	1.20 million shs	1.06 million shs
EDIT Editas Medicine	$3.15 +37.3%	$2.49	$0.91 ▼ $4.19	$261.60M	2.19	2.96 million shs	6.74 million shs
LRMR Larimar Therapeutics	$3.79 +2.3%	$3.20	$1.61 ▼ $9.50	$314.48M	0.93	1.06 million shs	1.07 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHG Bright Health Group	0.00%	-1.09%	-1.61%	-1.90%	+26.54%
CRGX CARGO Therapeutics	-0.45%	0.00%	-2.83%	+16.15%	-69.24%
EDIT Editas Medicine	+4.09%	-11.92%	-20.49%	+65.94%	-41.58%
LRMR Larimar Therapeutics	-2.12%	-1.07%	+9.47%	+106.70%	-51.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHG Bright Health Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	2.0313 of 5 stars	2.9	0.0	0.0	0.0	2.0	1.7	1.3
EDIT Editas Medicine	4.3816 of 5 stars	3.2	3.0	0.0	4.3	3.9	2.5	0.6
LRMR Larimar Therapeutics	2.8662 of 5 stars	3.6	2.0	0.0	0.0	3.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHG Bright Health Group	0.00	N/A	N/A	N/A
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	245.68% Upside
EDIT Editas Medicine	2.31	Hold	$4.90	55.80% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	388.77% Upside

Current Analyst Ratings Breakdown

Latest BHG, EDIT, LRMR, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHG Bright Health Group	$2.76B	0.02	N/A	N/A	($25.47) per share	-0.27
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
EDIT Editas Medicine	$35.84M	7.35	N/A	N/A	$1.63 per share	1.93
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHG Bright Health Group	-$1.46B	-$208.73	N/A	N/A	N/A	-85.40%	N/A	-10.26%	N/A
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/13/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/13/2025 (Estimated)

Latest BHG, EDIT, LRMR, and CRGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.40	-$0.63	-$0.23	-$0.63	$1.81 million	$3.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHG Bright Health Group	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHG Bright Health Group	N/A	1.04	1.04
CRGX CARGO Therapeutics	N/A	12.37	12.37
EDIT Editas Medicine	N/A	3.08	3.08
LRMR Larimar Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHG Bright Health Group	N/A
CRGX CARGO Therapeutics	93.16%
EDIT Editas Medicine	71.90%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
BHG Bright Health Group	58.40%
CRGX CARGO Therapeutics	2.92%
EDIT Editas Medicine	1.90%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHG Bright Health Group	2,840	7.98 million	3.32 million	Not Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable

BHG, EDIT, LRMR, and CRGX Headlines

Recent News About These Companies

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest

August 10 at 10:45 AM | finance.yahoo.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Director Buys $30,000,000.00 in Stock

August 5, 2025 | marketbeat.com

James E. Flynn Purchases 9,375,000 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock

August 5, 2025 | insidertrades.com

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Wednesday

August 4, 2025 | americanbankingnews.com

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

July 31, 2025 | globenewswire.com

Larimar Therapeutics shares drop following $60 million public offering

July 30, 2025 | msn.com

Larimar Therapeutics (LRMR) Expected to Announce Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock

July 29, 2025 | quiverquant.comQ

Larimar Therapeutics Announces Proposed Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

July 8, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)

June 24, 2025 | theglobeandmail.com

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

June 23, 2025 | globenewswire.com

Larimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development Program

June 22, 2025 | nasdaq.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

June 20, 2025 | finance.yahoo.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

June 20, 2025 | globenewswire.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock

May 24, 2025 | investing.com

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential

May 21, 2025 | insidermonkey.com

Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%

May 6, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BHG, EDIT, LRMR, and CRGX Company Descriptions

Bright Health Group NYSE:BHG

$6.75 +0.07 (+1.05%)

As of 08/12/2025

Bright Health Group, Inc., a healthcare company, provides health insurance policies in the United States. It operates in two segments, Bright HealthCare and Consumer Care. The Consumer Care segment delivers virtual and in-person clinical care services contracts through primary care clinics. It operates managed and affiliated risk-bearing clinics within its integrated care delivery system, which included embedded pharmacy, laboratory, radiology, and population health focused specialty services. The Bright HealthCare segment offers medicare health plan products to consumers. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is headquartered in Minneapolis, Minnesota.

CARGO Therapeutics NASDAQ:CRGX

$4.46 -0.01 (-0.11%)

As of 03:35 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Editas Medicine NASDAQ:EDIT

$3.14 +0.86 (+37.34%)

As of 03:36 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.78 +0.09 (+2.30%)

As of 03:36 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time